Innovative Single-Cell Platforms WaferGen offers advanced single-cell analysis systems like the ICELL8 and SmartChip platforms, providing unique opportunities for laboratories focused on biomarker validation, rare cell analysis, and personalized medicine. These technologies support high-throughput workflows suitable for pharmaceutical and clinical research clients seeking precise molecular insights.

Recent Acquisition Opportunity As part of Takara Bio USA since 2017, WaferGen's integration presents an opportunity to upsell complementary products and services from Takara Bio, especially to existing customers in genomics and life sciences, expanding reach into broader markets including precision diagnostics and research.

Growing Revenue Base With revenue estimates between 10 to 25 million dollars and a funding round of 15 million dollars, WaferGen is positioned for growth. Business development efforts can focus on expanding its client base in biotech, pharma, and clinical labs to accelerate sales of its innovative sequencing and analysis systems.

Target Market Expansion WaferGen's focus on high-throughput single-cell and molecular profiling technologies aligns well with current market trends emphasizing personalized medicine and next-generation sequencing. Sales strategies can highlight these trends to attract research institutions and clinical labs aiming to enhance their analytic capabilities.

Technological Differentiation The company’s proprietary automation systems and integrated platforms for DNA, RNA, and single-cell analysis offer unique selling points over competitors like QIAGEN or Illumina. Emphasizing these technological advantages can open sales opportunities with organizations seeking innovative, efficient solutions for complex genomic workflows.